NIH Gifts Brain Drug Patent to Psychedelic Biotech Firm
Published Date: 6/2/2025
Notice
Summary
The National Institutes of Health plan to give Psycala Bio, Inc. an exclusive license to use special new medicines that target the D2 dopamine receptor, which could help treat brain-related conditions. This means Psycala gets the sole right to develop and sell these drugs, potentially speeding up new treatments for patients. Keep an eye out for this exciting change, as it could impact healthcare and business soon!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Exclusive Patent License Granted
The National Institutes of Health is contemplating an Exclusive Patent License to Psycala Bio, Inc. for the inventions listed in the notice. Psycala Bio, Inc., incorporated in Delaware, would receive the exclusive rights to practice the patented inventions described in the Supplementary Information.
D2 Antagonists May Speed Treatments
The license covers exceptionally selective D2 dopamine receptor antagonists, which the notice says could help treat brain-related conditions. The contemplated grant to Psycala could potentially speed development of these therapies for patients.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in